13 June 2013Americas

US Supreme Court strikes Myriad blow

The US Supreme Court has ruled that isolated human DNA is not patent eligible and has struck down patents owned by biotech company Myriad, ending a long-running and controversial case.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Cantor Colburn tops list of law firms overturning Myriad rejections

25 August 2017 Law firm Cantor Colburn has achieved the highest rate of successful allowances for patent applications following section 101 rejections citing the Mayo and Myriad precedents, according to data compiled by research firm Juristat.

Myriad faces yet another patent battle

28 November 2013 Genetic diagnostics company Invitae Corporation has requested declaratory judgment at the US District Court for the Northern District of California that it does not infringe 11 patents owned or exclusively licensed to Myriad Genetics.

Myriad decision applied in diagnostic claims case

6 November 2013 The US District Court for the Northern District of California has found that diagnostic claims covering conventional detection methods do not make the use of a natural phenomenon patent eligible.

More on this story

Cantor Colburn tops list of law firms overturning Myriad rejections

25 August 2017 Law firm Cantor Colburn has achieved the highest rate of successful allowances for patent applications following section 101 rejections citing the Mayo and Myriad precedents, according to data compiled by research firm Juristat.

Myriad faces yet another patent battle

28 November 2013 Genetic diagnostics company Invitae Corporation has requested declaratory judgment at the US District Court for the Northern District of California that it does not infringe 11 patents owned or exclusively licensed to Myriad Genetics.

Myriad decision applied in diagnostic claims case

6 November 2013 The US District Court for the Northern District of California has found that diagnostic claims covering conventional detection methods do not make the use of a natural phenomenon patent eligible.

More on this story

Cantor Colburn tops list of law firms overturning Myriad rejections

25 August 2017 Law firm Cantor Colburn has achieved the highest rate of successful allowances for patent applications following section 101 rejections citing the Mayo and Myriad precedents, according to data compiled by research firm Juristat.

Myriad faces yet another patent battle

28 November 2013 Genetic diagnostics company Invitae Corporation has requested declaratory judgment at the US District Court for the Northern District of California that it does not infringe 11 patents owned or exclusively licensed to Myriad Genetics.

Myriad decision applied in diagnostic claims case

6 November 2013 The US District Court for the Northern District of California has found that diagnostic claims covering conventional detection methods do not make the use of a natural phenomenon patent eligible.

More features

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB